関: non-small-cell cancer

WordNet

small room in which a monk or nun lives (同)cubicle
a device that delivers an electric current as the result of a chemical reaction (同)electric cell
a room where a prisoner is kept (同)jail cell, prison cell
(biology) the basic structural and functional unit of all organisms; they may exist as independent units of life (as in monads) or may form colonies or tissues as in higher plants and animals
any small compartment; "the cells of a honeycomb"
a small unit serving as part of or as the nucleus of a larger political movement (同)cadre
type genus of the family Cancridae (同)genus Cancer
the fourth sign of the zodiac; the sun is in this sign from about June 21 to July 22 (同)Cancer the Crab, Crab
(astrology) a person who is born while the sun is in Cancer (同)Crab
a small zodiacal constellation in the northern hemisphere; between Leo and Gemini
any malignant growth or tumor caused by abnormal and uncontrolled cell division; it may spread to other parts of the body through the lymphatic system or the blood stream (同)malignant neoplastic disease

PrepTutorEJDIC

(刑務所の)『独房』;(修道院の)小さい独居室 / (ミツバチの)みつ房,巣穴 / 小さい部屋 / 『細胞』 / 電池 / 花粉室 / (共産党などの)細胞
〈U〉〈C〉『がん』 / 〈U〉〈C〉害悪 / 《Cancer》(星座の)カニ座

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 原発不明癌の分類およびマネージメントの概要 overview of the classification and management of cancers of unknown primary site
2. 頭頸部癌に対する治療の概要 overview of treatment for head and neck cancer
3. 肺癌の危険因子、病理、および臨床症状の概要 overview of the risk factors pathology and clinical manifestations of lung cancer
4. 非淡明細胞型腎癌に対する治療アプローチ the treatment approach to non clear cell renal carcinoma
5. 頭頚部癌の診断および病期分類の概要 overview of the diagnosis and staging of head and neck cancer

English Journal

Improved survival modeling in cancer research using a reduced piecewise exponential approach.

Han G, Schell MJ, Kim J.Author information Department of Biostatistics, Yale University School of Public Health, 60 College Street, New Haven, CT 06520, U.S.A.AbstractStatistical models for survival data are typically nonparametric, for example, the Kaplan-Meier curve. Parametric survival modeling, such as exponential modeling, however, can reveal additional insights and be more efficient than nonparametric alternatives. A major constraint of the existing exponential models is the lack of flexibility due to distribution assumptions. A flexible and parsimonious piecewise exponential model is presented to best use the exponential models for arbitrary survival data. This model identifies shifts in the failure rate over time based on an exact likelihood ratio test, a backward elimination procedure, and an optional presumed order restriction on the hazard rate. Such modeling provides a descriptive tool in understanding the patient survival in addition to the Kaplan-Meier curve. This approach is compared with alternative survival models in simulation examples and illustrated in clinical studies. Copyright © 2013 John Wiley & Sons, Ltd.
Statistics in medicine.Stat Med.2014 Jan 15;33(1):59-73. doi: 10.1002/sim.5915. Epub 2013 Jul 30.
Statistical models for survival data are typically nonparametric, for example, the Kaplan-Meier curve. Parametric survival modeling, such as exponential modeling, however, can reveal additional insights and be more efficient than nonparametric alternatives. A major constraint of the existing exponen
PMID 23900779

Stimulatory effects of sorafenib on human non‑small cell lung cancer cells in vitro by regulating MAPK/ERK activation.

Zhang YN, Wu XY, Zhong N, Deng J, Zhang L, Chen W, Li X, Zhong CJ.Author information Department of Thoracic Surgery, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, Jiangsu 215300, P.R. China.AbstractSorafenib is an inhibitor of a number of intracellular signaling kinases with antiproliferative, anti‑angiogenic and pro‑apoptotic effects in tumor cells. Sorafenib has been used in the therapy of advanced renal cell carcinoma. In the present study, using two human non‑small cell lung cancer (NSCLC)cell lines, A549 and NCI‑H1975, the effects of sorafenib on proliferation, apoptosis and intracellular signaling were systematically characterized. The results revealed that at a low concentration (5 µM) and early time point (6 h), sorafenib is capable of significantly stimulating proliferation of A549 cells, but not NCI‑H1975 cells. In addition, the comparison of the two cell lines revealed different cell cycle redistribution and apoptotic susceptibility to sorafenib at this concentration and time point. Western blot analysis revealed that sorafenib upregulated the expression of cyclin D1 and cyclin‑dependent kinase 2 and downregulated the expression of BAX at this specific point. Furthermore, sorafenib was confirmed to regulate the expression of cyclin D1 and apoptosis‑associated proteins through the regulation of extracellular signal‑regulated kinase 1/2 phosphorylation in A549 cells. These findings suggest that, although sorafenib has the potential for use in the treatment of renal cell carcinoma, this compound may also activate NSCLC cells at a specific time point.
Molecular medicine reports.Mol Med Rep.2014 Jan;9(1):365-9. doi: 10.3892/mmr.2013.1782. Epub 2013 Nov 7.
Sorafenib is an inhibitor of a number of intracellular signaling kinases with antiproliferative, anti‑angiogenic and pro‑apoptotic effects in tumor cells. Sorafenib has been used in the therapy of advanced renal cell carcinoma. In the present study, using two human non‑small cell lung cancer (
PMID 24213303

LUNX mRNA-positive cells at different time points predict prognosis in patients with surgically resected nonsmall cell lung cancer.

Li J1, Shi SB2, Shi WL2, Wang Y2, Yu LC2, Zhu LR2, Ge LP2.Author information 1Department of Pulmonary Medicine, Department of Thoracic Surgery, and Center of Experimental Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China. Electronic address: lijian541226@163.com.2Department of Pulmonary Medicine, Department of Thoracic Surgery, and Center of Experimental Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, China.AbstractLUNX is a lung-specific gene whose messenger ribonucleic acid (mRNA) expression is strictly limited to normal lung tissue and nonsmall cell lung cancer (NSCLC) tissue. The aim of this study was to investigate whether the detection of LUNX mRNA-positive circulating tumor cells (CTC)s in peripheral blood at different time points is useful for predicting disease recurrence, disease-free survival (DFS), and overall survival (OS) in NSCLC patients undergoing surgery. Serial blood samples from 68 patients with stage I-IIIA NSCLC were examined by real-time quantitative polymerase chain reaction assay targeting LUNX mRNA before (T0) and after surgery (T1) and after the completion of adjuvant chemotherapy (T2). Results showed that LUNX mRNA-positive CTCs were detected in 40 of 68 NSCLC patients (58.8%) before surgery; the detection rates of LUNX mRNA-positive CTCs at T1 and T2 time points were 32.4% (22/68) and 33.3% (20/60), respectively. The detection of LUNX mRNA-positive CTC at 3 time points was associated with lymph node status and pathologic stage. During the follow-up period, patients with LUXN mRNA-positive CTC at 3 time points had a higher relapse rate and a shorter DFS and OS than those without. Multivariate analysis revealed that presence of LUNX mRNA-positive CTC at T1 and T2 time points was an independent unfavorable factor for DFS and OS. In conclusion, detection of LUNX mRNA-positive CTC after surgery and the completion of adjuvant chemotherapy in patients with stage I-IIIA NSCLC are highly predictive for DFS and OS. This technique could aid in the prediction of prognosis and design of tailored treatment.
Translational research : the journal of laboratory and clinical medicine.Transl Res.2014 Jan;163(1):27-35. doi: 10.1016/j.trsl.2013.09.010. Epub 2013 Oct 10.
LUNX is a lung-specific gene whose messenger ribonucleic acid (mRNA) expression is strictly limited to normal lung tissue and nonsmall cell lung cancer (NSCLC) tissue. The aim of this study was to investigate whether the detection of LUNX mRNA-positive circulating tumor cells (CTC)s in peripheral bl
PMID 24120632

Japanese Journal

症例肺癌に対してペメトレキセドを含む化学療法施行中に関節リウマチを合併した2例

穴澤梨江,谷山大輔,鎌田浩史 [他]
日本呼吸器学会誌 = Annals of the Japanese Respiratory Society 2(3), 269-273, 2013-05-10
NAID 40019737455

3つの組織型を認めた異時性多発非小細胞肺癌の1切除例

岡田晃斉,佐々木正人,左近佳代,池田岳史,今村好章
日本呼吸器外科学会雑誌 = The journal of the Japanese Association for Chest Surgery 27(2), 164-169, 2013-03-15
NAID 10031138885

3つの組織型を認めた異時性多発非小細胞肺癌の1切除例

岡田晃斉,佐々木正人,左近佳代,池田岳史,今村好章
日本呼吸器外科学会雑誌 27(2), 164-169, 2013
間質性肺炎は肺癌発症の危険因子であり，異時性に肺癌が多発することもある．しかし，3つの組織型を発症した報告は稀である．今回，異時性に3つの組織型を発症した間質性肺炎合併肺癌症例を経験した．症例は66歳，女性．初回治療から約3年の経過で，扁平上皮癌，腺癌，大細胞神経内分泌癌の3組織型を認める肺癌を発症した．3回の手術加療を行い，現在再発巣に対し加療中である．間質性肺炎に肺癌が合併した場合，間質性肺炎 …
NAID 130003368758